The Irish-founded oncology software company, ONCOassist, today announces a new agreement with The National Comprehensive Cancer Network® (NCCN®). The collaboration will focus on integrating NCCN Content to create a digital tool that will help oncology professionals around the world stay up to date with relevant clinical content about cancer care.
By joining forces, NCCN enables ONCOassist to make key decision support information available to their users around the world, advancing their mission of helping HCPs make more-informed oncology decisions. The new agreement will allow oncology clinicians to access relevant, up-to-date tools and content at their fingertips on the ONCOassist smartphone app. ONCOassist and NCCN are working together to bring their content to oncology clinicians around the world, irrespective of their resources. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the healthcare delivery system.
Kerry-based ONCOassist has launched a clinical trial search engine with Cancer Trials Ireland. ONCOassist enables busy and under-pressure oncology clinicians to access relevant, up-to-date tools and content at their fingertips.
Irish app firm ONCOassist has launched a clinical trial search engine in partnership with clinical trial organization Cancer Trials Ireland. The search engine feature will be added to the ONCOassist app, which enables oncology clinicians to access relevant, up-to-date tools and content via their smart devices.
Irish oncology software company, ONCOassist, teams up with NCCN to improve day-to-day and patient care across 150 countries
The Irish oncology software company ONCOassist has announced an agreement with the National Comprehensive Cancer Network to develop a digital tool to help healthcare professionals. The collaboration will focus on integrating NCCN content to create a tool to support oncology professionals stay up to date with relevant clinical content about cancer care.
No one could have predicted all that has happened in healthcare this past 18 months. The unprecedented challenges of the global pandemic mean we now have fewer opportunities than ever to meet with patients. To meet this challenge, one valuable bridge between HCPs and patients that has emerged is a new generation of health tracking technology such as mobile health apps, artificial intelligence, epros, and robotics.
This week’s tech start-up of the week is Portable Medical Technology Ltd, a company that develops accredited and trusted apps for medical specialists to reduce medical errors, improve efficiencies and progress patient communication.
Mobile health, or mHealth, is the practice of public health and medicine through mobile devices. Co-founder & CEO of ONCOassist Eoin O’Carroll speaks to Health Tech World about the future of mHealth and its role amongst clinicians…
The Irish-founded oncology software company, ONCOassist, announces a new agreement with The National Comprehensive Cancer Network (NCCN). The collaboration will focus on integrating NCCN Content to create a digital tool that will help oncology professionals around the world stay up to date with relevant clinical content about cancer care. ONCOassist is a CE-approved decision support app for oncology professionals around the world. It is currently the only oncology app on the market with regulatory approval for use in a hospital setting.
KERRY MEDTECH APP ONCOassist has cut a deal with medical group MSD in Lebanon, opening the company up to the Middle East market. The app that provides information for oncologists will be partnering with the pharmaceutical company for a one-year trial to offer clinical content about cancer care across Lebanon.
I talk to Kevin Bambury the co-founder of ONCOassist. Kevin talks about his background, how ONCOassist started, what ONCOassist does, and what cancers it works with. Kevin also talks about how many countries use ONCOassist, why doctors should use ONCOassist, what devices their app works on, and where ONCOassist will go in the next 5 years.